Interpreting regulatory trials in epilepsy

Current Opinion in Neurology

Volumn 22, Issue 2, 2009, Pages 167-173

  Marson, Ag ^a,b   Williamson, Pr ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b Clinical Science Centre   (United Kingdom)

Author keywords

Active controlled designs; Antiepileptic drugs; Noninferiority; Placebo controlled; Randomized controlled trials

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; OXCARBAZEPINE; PHENYTOIN; PLACEBO; VALPROIC ACID;

ADD ON THERAPY; ANTICONVULSANT THERAPY; CLINICAL DECISION MAKING; CLINICAL TRIAL; DRUG APPROVAL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; EPILEPSY; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HUMAN; LICENSING; METHODOLOGY; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEIZURE; EUROPE; RISK FACTOR; TREATMENT OUTCOME; UNITED STATES;

ANTICONVULSANTS; DRUG APPROVAL; EPILEPSY; EUROPE; HUMANS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 68849091880     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283292427     Document Type: Review

References (37)

1. European Medicines Agency. Notes for guidance on clinical investigation of medicinalproductsinthetreatmentofepilepticdisorders[WebPage];http:// www.emea.europa.eu/pdfs/human/ewp/056698en.pdf.
2. Guidelines for clinical evaluation of antiepileptic drugs. Commission on antiepileptic drugs of the International League against epilepsy. Epilepsia 1989; 30:400-408.
3. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: asystematic review of their efficacy and tolerability. BMJ 1996; 313:1169-1174.
4. Cramer JA, Fisher R, Ben-Menachem E, et al. New antiepileptic drugs: comparison of key clinical trials. Epilepsia 1999; 40:590-600.
5. HughesDA,BayoumiAM,PirmohamedM.Currentassessmentofrisk-benefit by regulators: is it time to introduce decision analyses? Clin Pharmaco Ther 2007; 82:123-127.
6. Information From European Union Institutions and Bodies Commission. Guideline on the format and content of applications for agreement or modification of a paediatric investigation plan and requests for waivers or deferrals and concerning the operation of the compliance check and on criteria for assessing significant studies. [Web Page]. http://www.emea.eur-opa.eu/pdfs/ human/paediatrics/Guideline-2008-C243-01.pdf.
7. WalkerMC,LiLM,SanderJW.Long-termuseoflamotrigineandvigabatrinin severe refractory epilepsy: audit of outcome [see comments]. BMJ 1996; 313:1184-1185.
8. Kellett MW, Smith DF, Stockton PA, Chadwick DA. Topiramate in clinical practice: first years experience in a specialist epilepsy clinic. J Neurol Neurosurg Psychiatry 1999; 66:759-763.
9. Lhatoo SD, Wong IC, Polizzi G, Sander JW. Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia 2000; 41:1592-1596.
10. HemmingK,HuttonJL,MaguireMJ,MarsonAG.Openlabelextensionstudies- and patient selection biases. J Eval Clin Pract 2008; 14:141-144.
11. MaguireMJ,HemmingK,HuttonJL,MarsonAG.Overwhelmingheterogeneity- in systematic reviews of observational antiepileptic studies. Epilepsy Research 2008; 80:201-212.
12. Chadwick D, Privitera M. Placebo-controlled studies in neurology: where do they stop? Neurology 1999; 52:682-685.
13. Commission on antiepileptic drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia 1998; 39:799-803.
14. Leber P. Hazards of inference: the active control investigation. Epilepsia 1989; 30 (suppl 1):S57-S63.
15. Brodie MJ, Chadwick DW, Anhut H, et al. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia 2002; 43:993-1000.
16. Chadwick DW, Anhut H, Greiner MJ, et al. A double-blind trial of gaba-pentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-977. Neurology 1998; 51:1282-1288.
17. Wang SJ, Hung HM. Assessing treatment efficacy in noninferiority trials. Control Clin Trials 2003; 24:147-155.
18. Brodie MJ, Perucca E, Ryvlin P, et al., Levetiracetam Monotherapy Study Group.Comparisonoflevetiracetamandcontrolledreleasecarbamazepinein newly diagnoised epilepsy. Neurology 2007; 68:402-408.
19. Brodie MJ, Wroe SJ, Dean ADP, et al. Efficacy and safety of remacemide versus carbamazepine in newly diagnosed epilepsy: comparison by sequential analysis. Epilepsy Behav 2002; 3:140-146.
20. Marson AG, Williamson PR, Taylor S, et al. Efficacy of carbamazepine and valproate as monotherapy for early epilepsy and single seizures. Neurology 2006; 67:1872-1875.
21. The International Conference on Harmonisation of Technical Requirements- for Registration of Pharmaceuticals for Human Use. Choice of control group and related issues in clinical trials. [Web Page] http://www.ich.org/Media-Server. jser?@-ID=486&@-MODE=GLB.
22. ArroyoS,DodsonWE,PriviteraMD, et al. Randomizeddose-controlledstudy of topiramate as first-line therapy in epilepsy. Acta Neurol Scand 2005; 112:214-222.
23. GilliamFG,VelosoF,BomhofMA, et al. Adose-comparisontrialoftopiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 2003; 60:196-202.
24. Beydoun A, Fischer J, Labar DR, et al. Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83. Neurology 1997; 49:746-752.
25. Beydoun A,SachdeoRC,RosenfeldWE, et al. Oxcarbazepinemonotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial. Neurology 2000; 54:2245-2251.
26. Faught E, Sachdeo RC, Remler MP, et al. Felbamatemonotherapyforpartial- onset seizures: an active-control trial. Neurology 1993; 43:688-692.
27. GilliamF,VazquezB,SackellaresJC, et al. Anactive- controltrialoflamotrigine monotherapy for partial seizures. Neurology 1998; 51:1018-1025.
28. Sachdeo R, Kramer LD, Rosenberg A, Sachdeo S. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol 1992; 32:386-392.
29. SachdeoRC,ReifeRA,LimP,PledgerG.Topiramatemonotherapyforpartial onset seizures. Epilepsia 1997; 38:294-300.
30. Schachter SC, Vazquez B, Fisher RS, et al. Oxcarbazepine: double-blind, randomized,placebo-control,monotherapytrialforpartialseizures.Neurology 1999; 52:732-737.
31. Bourgeois B, Leppik I, Sackellares J, et al. Felbamate: a double blind controlled trial in patients undergoing presurgical evaluation of partial seizures. Neurology 1993; 43:693-696.
32. BergeyGK,MorrisHH,RosenfeldW, et al. Gabapentinmonotherapy:I.An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patientswithrefractorycomplexpartialorsecondarilygeneralizedseizures. The US Gabapentin Study Group 88/89. Neurology 1997; 49:739-745.
33. Marson AG, Al-Kharusi AM, Alwaidh M, et al., on behalf of the SANAD Study- group.Carbamazepine,gabapentin,lamotrigine,oxcarbazepineortopiramatefor partialepilepsy:resultsfromtheSANADtrial.Lancet2007;369:1000-1015.
34. MarsonAG,Al-KharusiAM,Alwaidh M, et al., onbehalfof theSANAD Study- group.Valproate,lamotrigineortopiramateforgeneralizedandunclassifiable epilepsy: results from the SANAD trial. Lancet 2007; 369:1016-1026.
35. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47:1094-1120.
36. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. London: National Institute for Clinical Excellence, 2004. Clinical Guideline 20.
37. The Scottish Intercollegiate Guideline Network. The diagnosis and management of epilepsy in adult. Guideline 70. http://www.sign.ac.uk/pdf/sign70. pdf.